Antineoplastic Agents, Phytogenic

• 

  Subject Areas on Research

  • A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma. 
  • A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme. 
  • A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. 
  • A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. 
  • A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study. 
  • A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer. 
  • A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. 
  • Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. 
  • Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. 
  • Aggressive multimodality treatment of invasive thymic carcinoma. 
  • An overview of naturally occurring histone deacetylase inhibitors. 
  • Anti-HIV Agents 45 and Antitumor Agents 205. Two New Sesquiterpenes, Leitneridanins A and B, and the Cytotoxic and Anti-HIV Principles from Leitneria floridana 
  • Anti-nociceptive roles of the glia-specific metabolic inhibitor fluorocitrate in paclitaxel-evoked neuropathic pain. 
  • Antitumor Agents, 138. Potenoids and Isoflavones as Cytotoxic Constituents of Amorpha fructicosa 
  • Antitumor Agents. 154. Cytotoxic and Antimitotic Flavonols from Polanisia dodecandra 
  • Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. 
  • Antitumor agents, 135. Structure and stereochemistry of polacandrin, a new cytotoxic triterpene from Polanisia dodecandra. 
  • Antitumor agents, 79. Cytotoxic antileukemic alkaloids from Brucea antidysenterica. 
  • Antitumor agents. 190. Absolute stereochemistry of the cytotoxic germacranolides, tomenphantins A and B, from Elephantopus tomentosus. 
  • Apparent elastic modulus and hysteresis of skeletal muscle cells throughout differentiation. 
  • Auto-SCT for AML in second remission: CALGB study 9620. 
  • Avastin: more questions than answers. . 
  • Bitter melon reduces head and neck squamous cell carcinoma growth by targeting c-Met signaling. 
  • CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine. 
  • Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex. 
  • Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient. 
  • Camptothecin analogues with enhanced antitumor activity at acidic pH. 
  • Camptothecin and Fas receptor agonists synergistically induce medulloblastoma cell death: ROS-dependent mechanisms. 
  • Carbamate derivatives of colchicine show potent activity towards primary acute lymphoblastic leukemia and primary breast cancer cells-in vitro and ex vivo study. 
  • Cardiotoxicities of paclitaxel in African Americans. 
  • Cardiotoxicities of paclitaxel in African Americans. 
  • Chemoradiation impairs myofiber hypertrophic growth in a pediatric tumor model. 
  • Combination regimens and dose intensification in non-small cell lung cancer: a panel discussion (Part 1). 
  • Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. 
  • Complex response of breast epithelial cell lines to topoisomerase inhibitors. 
  • Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. 
  • Cytoprotective effects of hematopoietic growth factors on primary human acute myeloid leukemias are not mediated through changes in BCL-2, bax, or p21WAF1/CIP1. 
  • Designing a broad-spectrum integrative approach for cancer prevention and treatment. 
  • Development of a cell-based, high-throughput screening assay for ATM kinase inhibitors. 
  • Docetaxel enhances tumor radioresponse in vivo. 
  • Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. 
  • Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma. 
  • Dual role of glutathione in modulating camptothecin activity: depletion potentiates activity, but conjugation enhances the stability of the topoisomerase I-DNA cleavage complex. 
  • Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. 
  • Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer. 
  • Effect of flaxseed supplementation on prostatic carcinoma in transgenic mice. 
  • Effect of perillic acid, a putative isoprenylation inhibitor, on the cultured rat lens. 
  • Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT. 
  • Effects of 10-hydroxycamptothecin, delivered from locally injectable poly(lactide-co-glycolide) microspheres, in a murine human oral squamous cell carcinoma regression model. 
  • Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. 
  • Enhanced method performance due to a shorter chromatographic run-time in a liquid chromatography-tandem mass spectrometry assay for paclitaxel. 
  • Enhanced pancreatic cancer gene therapy by combination of adenoviral vector expressing c-erb-B2 (Her-2/neu)-targeted immunotoxin with a replication-competent adenovirus or etoposide. 
  • Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma. 
  • Evaluation of new anticancer agents against human pancreatic carcinomas in nude mice. 
  • Evolving revascularization approaches for myocardial ischemia. 
  • Experience with irinotecan for the treatment of malignant glioma. 
  • Expression and Role of Voltage-Gated Sodium Channels in Human Dorsal Root Ganglion Neurons with Special Focus on Nav1.7, Species Differences, and Regulation by Paclitaxel. 
  • Extending principles learned in model systems to clinical trials design. 
  • Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer. 
  • Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. 
  • Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. 
  • Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. 
  • Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. 
  • Genetic Variants Associated With Vincristine-Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia. 
  • Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. 
  • Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. 
  • Hormone refractory prostate cancer: Management and advances. 
  • How paclitaxel can improve results in diabetics. 
  • Hypertensive reactions associated with paclitaxel. 
  • Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. 
  • Incidence and clinical relevance of abnormal complete blood counts in long-term survivors of childhood cancer. 
  • Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. 
  • Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. 
  • Intravascular ultrasound insights from the Cobalt Chromium Stent With Antiproliferative for Restenosis II (COSTAR II) trial comparing CoStar and Taxus paclitaxel-eluting stents. 
  • Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. 
  • Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. 
  • Irinotecan therapy in adults with recurrent or progressive malignant glioma. 
  • Irinotecan: promising activity in the treatment of malignant glioma. 
  • Is a reduction in radiation lung volume and dose necessary with paclitaxel chemotherapy for node-positive breast cancer? 
  • Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine. 
  • Kleinhospitine E and Cycloartane Triterpenoids from Kleinhovia hospita. 
  • Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. 
  • Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. 
  • Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. 
  • Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. 
  • Molecular biology of esophageal cancer. 
  • Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma. 
  • Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. 
  • Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. 
  • Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. 
  • Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. 
  • Notch3 pathway alterations in ovarian cancer. 
  • Novel luciferase-based reporter system to monitor activation of ErbB2/Her2/neu pathway noninvasively during radiotherapy. 
  • Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes. 
  • Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy. 
  • Overexpression of basic fibroblast growth factor (FGF-2) downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells. 
  • P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine). 
  • Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer. 
  • Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. 
  • Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. 
  • Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis. 
  • Paclitaxel-induced neuropathic hypersensitivity in mice: responses in 10 inbred mouse strains. 
  • Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. 
  • Paliasanines A-E, 3,4-Methylenedioxyquinoline Alkaloids Fused with a Phenyl-14-oxabicyclo[3.2.1]octane Unit from Melochia umbellata var. deglabrata. 
  • Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. 
  • Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. 
  • Phase II study of docetaxel in advanced soft tissue sarcomas. 
  • Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. 
  • Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. 
  • Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. 
  • Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. 
  • Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. 
  • Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. 
  • Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. 
  • Plant antitumor agents. 31. The calycopterones, a new class of biflavonoids with novel cytotoxicity in a diverse panel of human tumor cell lines. 
  • Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). 
  • Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. 
  • Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes. 
  • Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. 
  • Preferential extravasation and accumulation of liposomal vincristine in tumor comparing to normal tissue enhances antitumor activity. 
  • Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. 
  • Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. 
  • Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: involvement of NF-kappaB activation in drug resistance. 
  • Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma. 
  • Prospective Multicentered Safety and Feasibility Pilot for Endobronchial Intratumoral Chemotherapy. 
  • Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. 
  • Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. 
  • Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. 
  • Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. 
  • Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases. 
  • Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system. 
  • Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease? 
  • Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. 
  • Response of recurrent medulloblastoma to low-dose oral etoposide. 
  • Reversal of physiological stress-induced resistance to topoisomerase II inhibitors using an inducible phosphorylation site-deficient mutant of I kappa B alpha. 
  • Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. 
  • SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. 
  • Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD. 
  • Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. 
  • Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. 
  • Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma. 
  • Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). 
  • Stability-indicating LC assay of and impurity identification in homoharringtonine samples. 
  • Starting with the ABCs: Akt in breast cancer. 
  • Structure and stereochemistry of bryophyllin-A, a novel potent cytotoxic bufadienolide orthoacetate from Bryophyllum pinnatum. 
  • Successful clinical response to irinotecan in desmoplastic round blue cell tumor. 
  • Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 [corrected] 35INS. 
  • Sulfo-SMCC Prevents Annealing of Taxol-Stabilized Microtubules In Vitro. 
  • Survival and Causes of Death Among Veterans With Lower Extremity Revascularization With Paclitaxel-Coated Devices: Insights From the Veterans Health Administration. 
  • Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity. 
  • Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathic pain. 
  • Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. 
  • The Crystal Structure and Cytotoxicity of Goniodiol Monoacetate from Goniothalamus Amyon 
  • The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. 
  • The expression of HMGB1 on microparticles from Jurkat and HL-60 cells undergoing apoptosis in vitro. 
  • The extracellular release of HMGB1 during apoptotic cell death. 
  • The impact of tumor physiology on camptothecin-based drug development. 
  • The properties of microparticles from RAW 264.7 macrophage cells undergoing in vitro activation or apoptosis. 
  • Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice. 
  • Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. 
  • Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors. 
  • Thrombotic thrombocytopenic purpura that is refractory to therapeutic plasma exchange in two patients with occult infection. 
  • Thymic model for examining BRCA2 expression and function. 
  • Total syntheses of (-)-haemanthidine, (+)-pretazettine, and (+)-tazettine. 
  • Treatment of central nervous system xenografts with camptothecins. 
  • Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. 
  • Ultrasound guided pO2 measurement of breast cancer reoxygenation after neoadjuvant chemotherapy and hyperthermia treatment. 
  • Update in the management of patients with hormone-refractory prostate cancer. 
  • Update: vinorelbine (navelbine) in non-small cell lung cancer. 
  • Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. 
  • Vinorelbine tartrate (Navelbine): drug profile and nursing implications of a new vinca alkaloid. 
  • Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. 
  • Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. 
  • X-ray crystal structure of acrovestone, a cytotoxic principle from Acronychia pedunculata. 
  • Yin yang 1 modulates taxane response in epithelial ovarian cancer. 
  • [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. 
  • cis-parthenolid-9-one from Anvillea garcinii. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering